Biofrontera (BFRI) Q3 2026 Earnings Report

The call presented substantial regulatory, commercial, and operational progress, including a second approved indication, clearance of the RhodoLED XLC, strong revenue and volume growth, improved margins, and preparation for additional label expansion. However, these positives were offset by continued net losses, ITC-related costs, declining cash, a NASDAQ stockholders' equity deficiency, and management's disclosure that substantial doubt remains about the company's ability to continue as a going concern. Overall, the positive business developments and financial improvements were balanced by significant liquidity and compliance risks.

Management expects remediation of affected lamps to be “substantially complete by the end of the second quarter of 27,” to begin commercializing Ameluz for sBCC with a “full launch in the first quarter of 2027” after FDA feedback on marketing material, and to receive a PDUFA decision on the supplemental AK application on “August 5, 2027,” covering a treatment field of “up to 240 square centimeters”; management also said “Q4 typically our strongest quarter,” expects the “next $1 million milestone payment” in December, expects gross profit to be “back around our 80% mark,” believes there will be a “clear path to reimbursement upon launch,” and plans to address liquidity through revenue growth, a working line of credit, the milestone payment, and, if necessary, additional equity or debt.